Acelrx (ACRX) Gets a Hold Rating from Oppenheimer


Oppenheimer analyst Leland Gershell maintained a Hold rating on Acelrx (ACRX) today. The company’s shares opened today at $3.35.

According to TipRanks.com, Gershell is a 2-star analyst with an average return of 1.0% and a 54.0% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Anchiano Therapeutics Ltd, Avenue Therapeutics Inc, and Evofem Biosciences Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Acelrx with a $8.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $5.05 and a one-year low of $1.99. Currently, Acelrx has an average volume of 2.31M.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ACRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. Its products include sufentanil, DZUVEO, DSUVIA ZALVISO US and ZALVISO EU. The company was founded by Thomas A. Schreck and Pamela Pierce Palmer on July 13, 2005 and is headquartered in Redwood City, CA.